Does Switching from Coated Colchicine to Compressed Colchicine Improves Treatment Response in Patients with Familial Mediterranean Fever?

Overview

Journal Croat Med J

Specialty General Medicine

Date 2023 Nov 6

PMID 37927190

Authors

Nimet Oner

Elif Celikel

Zahide Ekici Tekin

Vildan Gungorer

Tuba Kurt

Muge Sezer

Nilufer Tekgoz

Cuneyt Karagol

Serkan Coskun

Melike Mehves Kaplan

Merve Cansu Polat

Banu Celikel Acar

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the treatment response to compressed colchicine tablets in familial Mediterranean fever (FMF) patients with resistance or intolerance to coated colchicine. The secondary aim was to determine the demographic and clinical characteristics of responders to compressed colchicine.

Methods: We retrospectively reviewed the medical records of 1574 pediatric patients with FMF treated at Ankara Bilkent City Hospital. Sixty-one patients did not respond to coated colchicine and were switched to compressed colchicine. In these patients, the number of attacks and the International Severity Score for FMF (ISSF) during the 6 months before and 3, 6, 9, 12, and 24 months after switching from coated colchicine to compressed colchicine were recorded.

Results: Twelve of 61 patients (19.7%) who were switched to compressed colchicine due to intolerance responded to treatment. Of the 49/61 patients (80.3%) who were switched due to uncontrolled attacks and persistent subclinical inflammation, 25 responded to treatment. The frequency of attacks and ISSF decreased after switching. At the end of the two-year follow-up, 42 patients responded to compressed colchicine, and 19 patients received compressed colchicine plus interleukin-1-targeting drugs.

Conclusions: Compressed colchicine was shown to be a useful treatment option before initiating biological agents in non-responders to coated colchicine, especially those with side effects.

Citing Articles

Familial Mediterranean Fever in Childhood.

Kisla Ekinci R, Kilic Konte E, Akay N, Gul U Turk Arch Pediatr. 2024; 59(6):527-534.

PMID: 39540697 PMC: 11562618. DOI: 10.5152/TurkArchPediatr.2024.24188.

References

Sahin N, Ozdemir Cicek S, Kisaarslan A, Poyrazoglu M, Gunduz Z, Dusunsel R . The remarkable characteristics of the children with colchicine-resistant familial Mediterranean fever in Turkey. Mod Rheumatol. 2021; 32(1):177-185. DOI: 10.1080/14397595.2021.1908502. View

Leung Y, Hui L, Kraus V . Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. PMC: 4656054. DOI: 10.1016/j.semarthrit.2015.06.013. View

Yalcinkaya F, Ozen S, Ozcakar Z, Aktay N, Cakar N, Duzova A . A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009; 48(4):395-8. DOI: 10.1093/rheumatology/ken509. View

Poddighe D, Romano M, Garcia-Bournissen F, Demirkaya E . Conventional and novel therapeutic options in children with familial Mediterranean fever: A rare autoinflammatory disease. Br J Clin Pharmacol. 2021; 88(6):2484-2499. DOI: 10.1111/bcp.15149. View

Turkucar S, Yener G, Dundar H, Acari C, Makay B, Yuksel S . Comparison of Different Pharmaceutical Preparations of Colchicine in Children with Familial Mediterranean Fever: Is Colchicine Opocalcium a Good Alternative?. Balkan Med J. 2020; 38(1):29-33. PMC: 8909219. DOI: 10.4274/balkanmedj.galenos.2020.2020.5.2205.220. View

Baglan E, Ozdel S, Bulbul M . Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever?. Mod Rheumatol. 2020; 31(2):481-484. DOI: 10.1080/14397595.2020.1790139. View

Weisenberg R, Borisy G, Taylor E . The colchicine-binding protein of mammalian brain and its relation to microtubules. Biochemistry. 1968; 7(12):4466-79. DOI: 10.1021/bi00852a043. View

Demirkaya E, Acikel C, Hashkes P, Gattorno M, Gul A, Ozdogan H . Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016; 75(6):1051-6. DOI: 10.1136/annrheumdis-2015-208671. View

Marko L, Shemer A, Lidar M, Grossman C, Druyan A, Livneh A . Anakinra for colchicine refractory familial Mediterranean fever: a cohort of 44 patients. Rheumatology (Oxford). 2021; 60(6):2878-2883. DOI: 10.1093/rheumatology/keaa728. View

10.

Sag E, Akal F, Atalay E, Kaya Akca U, Demir S, Demirel D . Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford). 2020; 59(11):3324-3329. DOI: 10.1093/rheumatology/keaa121. View

11.

van der Hilst J, Moutschen M, Messiaen P, Lauwerys B, Vanderschueren S . Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016; 10:75-80. PMC: 4831592. DOI: 10.2147/BTT.S102954. View

12.

Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M . Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013; 43(3):387-91. DOI: 10.1016/j.semarthrit.2013.04.011. View

13.

Emmungil H, Ilgen U, Turan S, Yaman S, Kucuksahin O . Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?. Rheumatol Int. 2019; 40(1):129-135. DOI: 10.1007/s00296-019-04432-3. View

14.

Sangiorgi E, Rigante D . The Clinical Chameleon of Autoinflammatory Diseases in Children. Cells. 2022; 11(14). PMC: 9318468. DOI: 10.3390/cells11142231. View

15.

Grossman C, Farberov I, Feld O, Livneh A, Ben-Zvi I . Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine. Rheumatol Int. 2019; 39(3):517-523. DOI: 10.1007/s00296-018-04237-w. View

16.

Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R . Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 2005; 4(1):117-24. DOI: 10.2174/1568010053622984. View

17.

Deftereos S, Giannopoulos G, Vrachatis D, Siasos G, Giotaki S, Gargalianos P . Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020; 3(6):e2013136. PMC: 7315286. DOI: 10.1001/jamanetworkopen.2020.13136. View

18.

Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S . Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2016; 69(4):854-862. DOI: 10.1002/art.39995. View

19.

Erten S, Erten S, Altunoglu A . Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatol Int. 2011; 32(4):1095-7. DOI: 10.1007/s00296-011-1855-5. View

20.

Yalcin Kehribar D, Ozgen M . Efficacy of anti-interleukin-1 treatment in colchicine-resistant arthritis in patients with familial Mediterranean fever. Eur J Rheumatol. 2020; 8(1):16-19. PMC: 7861647. DOI: 10.5152/eurjrheum.2020.20126. View